CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 6.18: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.61%
Annual Rate
CNY 0.36Paid semi-annual
Payout Ratio
10.4%Sustainable
Payback Period
94.2 yr
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.87BCNY1.17B · vs all stocks (USD)
Trailing P/E
34.24xRevenue (TTM)
1.45BCNY216.62M · vs all stocks (USD)
Profit Margin
15.97%Beta
0.1890xvs all stocks
52-Week Change
1.82%vs all stocks
Forward Annual Dividend Yield
0.61%vs all stocks
Market Capitalization
7.87BCNY1.17B · vs all stocks (USD)
Enterprise Value
8.36BCNY1.25B · vs all stocks (USD)
Trailing P/E
34.24xForward P/E
39.29xPrice to Sales (TTM)
5.42xPrice to Book (MRQ)
3.71xEnterprise to Revenue
5.76xEnterprise to EBITDA
36.09xGross Margin
55.78%Profit Margin
15.97%Operating Margin
11.27%Return on Assets (TTM)
3.30%Return on Equity (TTM)
11.58%Revenue (TTM)
1.45BCNY216.62M · vs all stocks (USD)
Revenue per Share (TTM)
11.02CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-10.90%Gross Profit (TTM)
844.95MCNY126.13M · vs all stocks (USD)
EBITDA (TTM)
237.82MCNY35.50M · vs all stocks (USD)
Net Income (TTM)
231.76MCNY34.60M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
26.20%Operating Cash Flow (TTM)
384.86MCNY57.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-334.99MCNY-50.00M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3576CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
0.61%vs all stocks
Trailing Annual Dividend Rate
0.6074CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.03%vs all stocks
Payout Ratio
10.40%Revenue
1.50BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
597.40MCNYFY2025 · Dec 31, 2025Gross Profit
906.83MCNYFY2025 · Dec 31, 2025Operating Income
165.64MCNY24.73M · vs all stocks (USD)
Pre-tax Income
240.90MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.80MCNYFY2025 · Dec 31, 2025Net Income
228.10MCNYFY2025 · Dec 31, 2025EBIT
241.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
322.29MCNYFY2025 · Dec 31, 2025Research & Development
129.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
523.43MCNYFY2025 · Dec 31, 2025Other Operating Expenses
14.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
647.37KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.81CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.77CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
131.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
131.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
228.10MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.18MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
191.50MCNYFY2025 · Dec 31, 2025Free Cash Flow
-328.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
201.48MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
228.10MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.42MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-56.44MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.43MCNYFY2025 · Dec 31, 2025Capital Expenditures
-520.24MCNYFY2025 · Dec 31, 2025Net Acquisitions
5.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-733.47MCNYFY2025 · Dec 31, 2025Sale of Investments
645.14MCNYFY2025 · Dec 31, 2025Other Investing Activity
-6.56MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-609.17MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
384.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-62.96MCNYFY2025 · Dec 31, 2025Other Financing Charges
14.97MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
336.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
133.64MSharesUpdated Sep 22, 2026Float Shares
62.54MSharesUpdated Sep 22, 2026% Held by Insiders
48.60%vs all stocks
% Held by Institutions
6.19%vs all stocks
Total Cash (MRQ)
288.51MCNY43.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.16CNYUpdated Sep 22, 2026Total Debt (MRQ)
774.12MCNY115.55M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3645xCurrent Ratio (MRQ)
2.57xBook Value per Share (MRQ)
15.89CNYUpdated Sep 22, 2026Total Assets
3.05BCNY455.82M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
600.26MCNYFY2025 · Dec 31, 2025Total Current Liabilities
410.70MCNYFY2025 · Dec 31, 2025Cash
201.48MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
203.78MCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
210.38MCNYFY2025 · Dec 31, 2025Inventory
392.46MCNYFY2025 · Dec 31, 2025Accounts Payable
181.53MCNYFY2025 · Dec 31, 2025Short-term Debt
371.00KCNYFY2025 · Dec 31, 2025Other Current Liabilities
21.05MCNYFY2025 · Dec 31, 2025Long-term Debt
497.60MCNYFY2025 · Dec 31, 2025Common Stock (Book)
131.32MCNYFY2025 · Dec 31, 2025Retained Earnings
990.46MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.04BCNY304.91M · vs all stocks (USD)
52-Week Low
40.33CNYUpdated Sep 22, 202652-Week High
65.20CNYUpdated Sep 22, 202652-Week Change
1.82%vs all stocks
Beta
0.1890xvs all stocks
50-Day MA
47.11CNYUpdated Sep 22, 2026200-Day MA
49.58CNYUpdated Sep 22, 2026Avg 10-Day Volume
3.02MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.91MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.72CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.18: safe zoneNotable
Altman Z-Score: 6.18
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novogene Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule